Pyoderma gangrenosum is a rare and painful skin condition that causes open sores on the body. Treatment aims to control inflammation, promote wound healing, reduce pain, and prevent complications such as scarring and infection. Managing pyoderma gangrenosum can be challenging, but a combination of standard medicines and emerging therapies offers hope for better outcomes.

Understanding Your Treatment Options

When someone develops pyoderma gangrenosum, the journey to healing is rarely straightforward. This condition doesn’t respond to typical wound care alone, and the approach must address the underlying inflammatory process – the body’s immune system mistakenly attacking healthy skin tissue. The treatment path depends on several factors, including how severe the ulcers are, how quickly they’re growing, where they’re located on the body, and whether you have other health conditions that might be connected to pyoderma gangrenosum.^[1][2]

Most people with pyoderma gangrenosum will need medicines that calm down or suppress the immune system. These are different from antibiotics, because pyoderma gangrenosum is not caused by an infection, despite how the name sounds. The word “pyoderma” might suggest pus and infection, but this condition is actually an inflammatory disorder where a type of white blood cell called neutrophils builds up excessively in the skin.^[4][5]

Early diagnosis and treatment are crucial. The longer pyoderma gangrenosum goes untreated, the larger and deeper the ulcers can become, and the longer they take to heal. Many patients experience delays in diagnosis because the condition is rare and can look like other problems such as infections, insect bites, or blood vessel inflammation.^[3][7]

Standard Treatment Approaches

The cornerstone of pyoderma gangrenosum treatment involves medicines that reduce inflammation and calm the overactive immune response. The most commonly used treatments are corticosteroids and a medicine called cyclosporine. These form the backbone of therapy for most patients.^[10][11]

Corticosteroids, such as prednisone, are often the first choice for treating pyoderma gangrenosum. They work by powerfully reducing inflammation throughout the body. Doctors may prescribe them as tablets to be taken by mouth, as creams or ointments to apply directly to the skin, or as injections directly into the wound edges. For severe or rapidly spreading ulcers, high doses of oral corticosteroids are typically needed to bring the condition under control quickly.^[10][13]

However, using high doses of corticosteroids for extended periods can cause significant side effects. These may include weight gain, mood changes, increased blood sugar levels, weakened bones, higher risk of infections, and changes in appearance such as a rounded face or increased body hair. Because of these risks, doctors often try to use steroids for the shortest time necessary, or combine them with other medicines that allow the steroid dose to be reduced.^[10]

Cyclosporine is another key medicine used to treat pyoderma gangrenosum. It’s an immunosuppressant – a drug that suppresses or weakens the immune system’s activity. Cyclosporine works by specifically targeting the immune cells involved in causing inflammation. Some doctors choose cyclosporine as the initial treatment instead of corticosteroids, especially for certain types of pyoderma gangrenosum. It can also be used in combination with steroids.^[6][11]

Other immunosuppressive medicines used for pyoderma gangrenosum include azathioprine, mycophenolate mofetil, cyclophosphamide, tacrolimus, and chlorambucil. These drugs are often added when high-dose, long-term steroid treatment is anticipated, or when steroids alone aren’t working well enough. They act as “steroid-sparing” agents, meaning they allow doctors to reduce the steroid dose while still controlling the disease.^[10][13]

Dapsone is an antibiotic-like medicine that also has anti-inflammatory properties. It’s sometimes used for milder cases of pyoderma gangrenosum or as part of combination therapy. Another antibiotic called minocycline may also be tried, not because pyoderma gangrenosum is an infection, but because some antibiotics have immune-modulating effects.^[7][9]

Healing can take a long time – often weeks to months – even with effective treatment. The sores may leave scars after healing, sometimes with a distinctive criss-cross pattern. It’s also common for new ulcers to develop while older ones are healing, which can be frustrating for patients.^[2][10]

Caring for the Wound

Alongside medicines that treat the underlying inflammation, proper wound care is essential. The goals are to protect the ulcer, manage fluid leaking from the wound, reduce pain, and prevent secondary bacterial infections. Gentle cleaning and modern wound dressings are preferred. Dressings may include creams, ointments, specialized bandages, and materials that absorb fluid. Some dressings contain substances like cadexomer iodine that help reduce bacteria in the wound.^[2][4]

Topical treatments applied directly to the skin include very strong corticosteroid creams or ointments. Another type of topical medicine called calcineurin inhibitors (such as tacrolimus ointment) may also be used. These are particularly helpful for milder disease or as additional support for systemic treatment.^[7][9]

Innovative Treatments Being Studied in Clinical Trials

Because pyoderma gangrenosum is rare, large-scale clinical trials have been difficult to conduct. However, researchers are actively exploring newer treatments, particularly biologic therapies – medicines made from living cells that target very specific parts of the immune system. These newer treatments are showing promise for patients who don’t respond well to standard medicines or who can’t tolerate the side effects.^[11][13]

TNF-Alpha Inhibitors

One group of biologics that has shown good results in pyoderma gangrenosum are tumor necrosis factor-alpha (TNF-α) inhibitors. TNF-alpha is a chemical messenger in the body that promotes inflammation. By blocking its action, these medicines can reduce the inflammatory damage in pyoderma gangrenosum. Several TNF-α inhibitors are being used or studied for this condition.^[11]

Infliximab is a TNF-α inhibitor given through a vein (intravenously). It has been studied in clinical trials and case reports for pyoderma gangrenosum, particularly in patients who also have inflammatory bowel disease (such as Crohn’s disease or ulcerative colitis). Studies have shown that infliximab can lead to rapid improvement in pyoderma gangrenosum ulcers. This medicine is becoming increasingly considered as a first-line option, especially for severe cases or when there’s an associated inflammatory condition.^[4][10][13]

Other TNF-α inhibitors used for pyoderma gangrenosum include adalimumab, etanercept, certolizumab, and golimumab. These medicines are injected under the skin rather than given intravenously. They work in similar ways to infliximab and have shown benefit in various case reports and smaller studies.^[13]

Interleukin Inhibitors

Another frontier in pyoderma gangrenosum treatment involves medicines that block substances called interleukins (IL). These are chemical messengers that help coordinate immune responses. In pyoderma gangrenosum, certain interleukins may be overactive, driving excessive inflammation.^[11]

Ustekinumab is a biologic that blocks interleukin-12 and interleukin-23. It has been studied in clinical trials for pyoderma gangrenosum, both as an intravenous treatment and as an injection under the skin. Some patients who haven’t responded to other treatments have shown improvement with ustekinumab.^[13]

Newer medicines targeting interleukin-23 specifically are being explored. These include risankizumab and guselkumab, which are already approved for other inflammatory conditions like psoriasis. Early reports suggest they may help some patients with pyoderma gangrenosum.^[13]

There’s also interest in medicines that block interleukin-1 and interleukin-17, which are involved in neutrophil activity and inflammation. Canakinumab, an interleukin-1β inhibitor, showed effectiveness in a patient who had both pyoderma gangrenosum and another inflammatory skin condition called hidradenitis suppurativa.^[13]

JAK Inhibitors

A particularly exciting development is the use of JAK inhibitors – medicines that block enzymes called Janus kinases, which play a role in many inflammatory pathways. These are small-molecule drugs taken by mouth, offering a different approach than injected biologics.^[11][13]

Upadacitinib is one such JAK inhibitor that has shown promise. In a published case report, a 62-year-old woman with severe, steroid-resistant pyoderma gangrenosum and ulcerative colitis was successfully treated with upadacitinib. The medicine helped control both conditions. This type of dual benefit is particularly valuable for patients whose pyoderma gangrenosum is associated with inflammatory bowel disease.^[15]

Other JAK inhibitors being studied include medicines that target specific Janus kinase enzymes. These treatments are still being investigated, but they represent a promising option for patients who haven’t found success with other therapies.^[13]

Other Investigational Approaches

Researchers are also looking at blocking complement factor C5a, a part of the immune system involved in directing neutrophils to sites of inflammation. Medicines targeting this pathway are in development for pyoderma gangrenosum.^[11]

Some doctors have tried intravenous immunoglobulin (IVIG), which is a treatment made from antibodies pooled from many blood donors. There are reports of patients improving with this therapy, though it’s not widely used and more research is needed.^[10][13]

Other medicines occasionally tried include thalidomide, a medicine with immune-modulating effects, and clofazimine, an antimicrobial with anti-inflammatory properties. Some treatment centers have even explored hyperbaric oxygen therapy, where patients breathe pure oxygen in a pressurized chamber, though evidence for its effectiveness is limited.^[13]

Understanding Clinical Trial Phases

When new treatments are tested, they go through different phases of clinical trials. Phase I trials focus on safety – they test whether a treatment is safe enough to use in humans and what dose is appropriate. Phase II trials look at whether the treatment actually works (efficacy) in a small group of patients. Phase III trials are larger studies that compare the new treatment to existing standard treatments to see if it’s better, as good, or has fewer side effects. Most of the newer treatments for pyoderma gangrenosum are still in earlier phases or are being studied through case reports and small case series rather than large randomized trials, because the condition is so rare.^[11]

Most Common Treatment Methods

• Corticosteroids (Anti-inflammatory medicines)
  • Oral corticosteroids such as prednisone taken by mouth to reduce inflammation throughout the body
  • Topical corticosteroid creams or ointments applied directly to ulcers
  • Corticosteroid injections into the edges of wounds
  • Pulsed intravenous methylprednisolone for severe cases
• Immunosuppressive Medicines
  • Cyclosporine to suppress specific immune system activity
  • Azathioprine as a steroid-sparing agent
  • Mycophenolate mofetil to reduce immune response
  • Tacrolimus, either systemic or as a topical ointment
  • Cyclophosphamide for resistant cases
  • Chlorambucil in combination therapy
• Biologic Therapies (TNF-alpha Inhibitors)
  • Infliximab given intravenously, particularly effective for rapid response
  • Adalimumab injected under the skin
  • Etanercept as an alternative TNF-alpha blocker
  • Certolizumab and golimumab for patients not responding to other TNF inhibitors
• Interleukin Inhibitors
  • Ustekinumab blocking IL-12 and IL-23 pathways
  • Risankizumab targeting IL-23 specifically
  • Guselkumab as another IL-23 inhibitor
  • Canakinumab blocking IL-1β in selected cases
• JAK Inhibitors
  • Upadacitinib, an oral medicine blocking Janus kinase enzymes
  • Other selective JAK inhibitors under investigation
• Antibiotics with Anti-inflammatory Properties
  • Dapsone for milder cases or as combination therapy
  • Minocycline for its immune-modulating effects
• Topical Therapies
  • Calcineurin inhibitors such as tacrolimus ointment
  • Topical 5-aminosalicylic acid (5-ASA)
  • Cromolyn sodium solution
• Wound Care and Dressings
  • Modern absorptive dressings to manage wound fluid
  • Cadexomer iodine to reduce bacterial load
  • Gentle cleansing to avoid triggering pathergy
  • Bandages and protective coverings
• Other Therapies
  • Intravenous immunoglobulin (IVIG) for refractory cases
  • Thalidomide as an immune modulator
  • Hyperbaric oxygen therapy in select treatment centers
  • Nicotine therapy being explored

Living With Pyoderma Gangrenosum

The impact of pyoderma gangrenosum extends far beyond the physical wounds. Many patients experience severe pain that disrupts sleep and makes daily activities difficult. The pain can be disproportionate to the size of the ulcer and often feels like burning or throbbing. Good pain management is an essential part of treatment and may require medications specifically for pain control, sometimes including strong pain medicines.^[17][19]

The emotional and psychological toll can be significant. Patients often face delays in diagnosis, with the condition being mistaken for an infection or other problem. This can lead to unnecessary treatments, including surgeries that may make things worse. The visible nature of the ulcers and the long healing time can affect self-esteem, social interactions, and mental health. Some patients develop anxiety or depression as they cope with the chronic nature of the disease.^[17]

For patients whose pyoderma gangrenosum is linked to another condition like inflammatory bowel disease or rheumatoid arthritis, treating the underlying disease can sometimes help control the skin ulcers. This is why it’s important for your doctor to check for these associated conditions.^[1][2]

Preventing injury to the skin is important because even minor trauma can trigger new ulcers through the pathergy phenomenon. This means being careful to avoid cuts, scrapes, and unnecessary skin procedures. If surgery is absolutely needed, it should be carefully planned and coordinated with medical treatment to minimize the risk of new ulcers forming.^[5][6]

Most patients need ongoing follow-up care with specialists, typically a dermatologist (skin specialist) or sometimes a rheumatologist (specialist in autoimmune and inflammatory diseases). Complex cases may require a team approach involving wound care specialists, pain management experts, and mental health professionals.^[3][7]

While pyoderma gangrenosum can be challenging to manage, with proper treatment most ulcers will eventually heal. However, the prognosis remains somewhat unpredictable, and recurrence is possible even after successful treatment. Scarring is common, and the appearance of scars can vary – they may be darker or paler than surrounding skin, thin and wrinkled, or have a pitted appearance.^[4][7]